Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: Effect of miglitol (Bay m1099)

Metabolism: Clinical and Experimental

Volumn 48, Issue 6, 1999, Pages 701-706

  Russell, J C ^a   Graham, S E ^b   Dolphin, P J ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID; MIGLITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CHRONOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HEART PROTECTION; INSULIN METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0033001602     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90168-3     Document Type: Article

References (39)

1. Després J-P, Moorjani S, Lupien PJ, et al: Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497-511, 1990
2. Steiner G: Hyperinsulinemia and hypertriglyceridemia. J Intern Med 736:23-26, 1994 (suppl)
3. Koletsky S: Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80:129-142, 1975
4. Greenhouse DD, Michaelis OE, Peterson RG: The development of fatty and corpulent rat strains, in Hansen CT, Michaelis OE (eds): New Models of Genetically Obese Rats for Studies in Diabetes, Heart Disease, and Complications of Obesity. Bethesda, MD, National Institutes of Health, 1988, pp 3-6
5. Wu-Peng XS, Chua SC Jr, Okada N, et al: Phenotype of the obese Koletsky (f) rat due to Tyr763 stop mutation in the extracellular domain of the leptin receptor (Lepr). Diabetes 46:513-518, 1997
6. Russell JC, Ahuja SK, Manickavel V, et al: Insulin resistance and impaired glucose tolerance in the atherosclerosis prone LA/N-corpulent rat. Arteriosclerosis 7:620-626,1987
7. Russell JC, Graham S, Hameed M: Abnormal insulin and glucose metabolism in the JCR:LA-corpulent rat. Metabolism 43:538-543, 1994
8. Russell JC, Koeslag DG, Amy RM, et al: Plasma lipid secretion and clearance in hyperlipidemic JCR:LA-corpulent rats. Arteriosclerosis 9:869-876, 1989
9. Vance J, Russell JC: Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat. J Lipid Res 31:1491-1501, 1990
10. Russell JC, Amy RM: Myocardial and vascular lesions in the LA/N-corpulent rat. Can J Physiol Pharmacol 64:1272-1280, 1986
11. Russell JC: The atherosclerosis-prone JCR:LA-corpulent rat, in Woodford FP, Davignon J, Sniderman A (eds): Atherosclerosis X: Proceedings of the 10th International Symposium on Atherosclerosis. Amsterdam, The Netherlands, Elsevier, 1995, pp 121-125
12. Russell JC, Amy RM, Manickavel V, et al: Effects of chronic ethanol consumption in atherosclerosis-prone JCR:LA-corpulent rat. Arteriosclerosis 9:122-128, 1989
13. Russell JC, Amy RM, Manickavel V, et al: Prevention of myocardial disease in JCR:LA-corpulent rats by running. J Appl Physiol 66:1649-1655, 1989
14. Russell JC, Dolphin PJ, Graham SE, et al: Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. Diabetologia 41:380-389, 1998
15. Russell JC, Amy RM, Graham SE, et al: Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by β,β′-tetramethylhexadecanedioic acid (MEDICA 16). Arterioscler Thromb Vase Biol 15:918-923, 1995
16. Russell JC, Amy RM, Koeslag DG, et al: Independence of myocardial disease in the JCR:LA-corpulent rat of plasma cholesterol concentration. Clin Invest Med 14:288-295, 1991
17. Russell JC, Koeslag DG, Dolphin PJ, et al: Prevention of myocardial lesions in JCR:LA-corpulent rats by nifedipine. Arteriosclerosis 10:658-664, 1990
18. Russell JC, Dolphin PJ, Graham SE, et al: Cardioprotective and hypolipidemic effects of nisoldipine in the JCR:LA-cp rat. J Cardiovasc Pharmacol 29:586-592, 1997
19. O'Brien SF, McKendrick JD, Radomski MW, et al: Vascular wall reactivity in conductance and resistance arteries: Differential effects of insulin resistance. Can J Physiol Pharmacol 76:72-76, 1998
20. Richardson M, Schmidt AM, Graham SE, et al: Vasculopathy and insulin resistance in the JCR:LA-cp rat. Atherosclerosis 138:135-146, 1998
21. O'Brien SF, Russell JC: Insulin resistance and vascular wall function: Lessons from animal models. Endocrinol Metab 4:155-162, 1997 (review)
22. Katsilambros N, Philippides P, Toskas A, et al: A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics. Arzneimittelforschung 36:1136-1138, 1986
23. Sels JP, Nauta JJ, Menheere PP, et al: Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers. Br J Clin Pharmacol 42:503-506, 1996
24. Russell JC, Amy RM, Dolphin PJ: Effect of dietary n-3 fatty acids on atherosclerosis prone JCR:LA-corpulent rats. Exp Mol Pathol 55:285-293, 1991
25. Kuksis A, Myher JJ, Geher K, et al: Comparative determination of plasma cholesterol and triacylglycerol levels by automated gas-liquid chromatographic and autoanalyzer techniques. J Chromatogr 146:393-412, 1978
26. De Lean A, Munson PJ, Rodbard D: Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235:E97-E102, 1978
27. Heath DF, Frayne KN, Rose JG: Rates of glucose utilization and glucogenesis in rats in the basal state induced by halothane anesthesia. Biochem J 162:643-651, 1977
28. Leza JC, Salas E, Sawicki G, et al: The effect of stress on homeostasis in JCR:LA-cp rats. Role of nitric oxide. J Pharmacol Exp Ther 28:1397-1403, 1998
29. McArthur MD, Graham SE, Russell JC, et al: Exaggerated stress-induced release of non-esterified fatty acids in JCR:LA-corpulent rats. Metabolism 47:1383-1390, 1998
30. Pederson RA, Campos RV, Buchan AMJ, et al: Comparison of the enteroinsular axis in two strains of obese rats: The fatty Zucker and JCR:LA-corpulent. Int J Obes 15:461-470, 1991
31. Emilsson V, Lim YL, Cawthorne MA, et al: Expression of the functional leptin receptor in RNA in pancreatic islets and directly inhibitory action of leptin on insulin secretion. Diabetes 46:313-316, 1997
32. Chua SC Jr, White DW, Wu-Peng XS, et al: Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 45:1141-1143, 1996
33. Ahr HJ, Boberg M, Brendel E, et al: Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 47:734-745, 1997
34. Russell JC, Graham SE, Dolphin PJ, et al: Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat. Can J Physiol Pharmacol 74:879-886, 1996
35. Russell JC, Bar-Tana J, Shillabeer G, et al: Development of insulin resistance in the JCR:LA-cp rat: Role of triacylglycerols and effects of MEDICA16. Diabetes 47:770-778, 1998
36. Tulp OL, Szepesi B, Michaelis OE IV, et al: The effects of low-dose Bay-M-1099 (miglitol) on serum lipids and liver enzyme activity of obese and obese-diabetic corpulent rats. Comp Biochem Physiol 99:241-246, 1991
37. DeBuono JF, Michaelis OE IV, Tulp OL: The effects of intestinal glucosidase in inhibitory Bay M1099 (miglitol) on glycemi cstatus of obese-diabetic rats. Gen Pharmacol 24:504-515, 1993
38. Bollen M, Vandebroeck A, Stalmans W: 1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase a. Biochem Pharmacol 37:905-909, 1988
39. Russell JC, Koeslag DG, Dolphin PJ, et al: Beneficial effects of acarbose in the atherosclerosis-prone JCR:LA-corpulent rat. Metabo-lism 42:218-223, 1993